MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer-Trial in progress.

被引：0

作者：

Bekaii-Saab, Tanios S.

Van Cutsem, Eric

Tabernero, Josep

Siena, Salvatore

Yoshino, Takayuki

Nakamura, Yoshiaki

Raghav, Kanwal Pratap Singh

Cercek, Andrea

Heinemann, Volker

Adelberg, David E.

Ward, James Edward

Yang, Shan

Andre, Thierry

Strickler, John H.

机构：

[1] Mayo Clin, Scottsdale, AZ USA

[2] Univ Hosp Gasthuisberg, Leuven, Belgium

[3] Univ Leuven, Leuven, Belgium

[4] Vall DHebron Univ Hosp & Inst Oncol VHIO, Barcelona, Spain

[5] Grande Osped Metropolitano Niguarda, Milan, Italy

[6] Univ Milan, Milan, Italy

[7] Natl Canc Ctr Hosp Japan East, Kashiwa, Chiba, Japan

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[10] Univ Munich, Munich, Germany

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Seagen Inc, Bothell, WA USA

[13] Sorbonne Univ, Paris, France

[14] Hop St Antoine, INSERM Instabil Microsatellites & Canc, Paris, France

[15] Duke Univ, Med Ctr, Durham, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS261

引用

页码：TPS261 / TPS261

页数：1

共 50 条

[31] Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer
Gilcrease, G. Weldon
Stenehjem, David D.
Wade, Mark L.
Weis, John
McGregor, Kimberly
Whisenant, Jonathan
Boucher, Kenneth M.
Thorne, Kelli
Orgain, Nicole
Garrido-Laguna, Ignacio
Sharma, Sunil
INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 482 - 489
[32] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER
Graham, C. N.
Hechmati, G.
Hjelmgren, J.
De Liege, F.
Lanier, J.
Knoof, A.
Knox, H.
Barber, B.
de Pouvourville, G.
VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
[33] A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 ns first-line treatment for metastatic colorectal cancer (mCRC); Interim results.
Hecht, J. R.
Yoshio, T.
Mitchell, E. P.
Dees, M. S., III
Countouriotis, A. M.
Maneval, E. C.
Kretzschmar, A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[34] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
van Hazel, Guy A.
Heinemann, Volker
Sharma, Navesh K.
Findlay, Michael P. N.
Ricke, Jens
Peeters, Marc
Perez, David
Robinson, Bridget A.
Strickland, Andrew H.
Ferguson, Tom
Rodriguez, Javier
Kroening, Hendrik
Wolf, Ido
Ganju, Vinod
Walpole, Euan
Boucher, Eveline
Tichler, Thomas
Shacham-Shmueli, Einat
Powell, Alex
Eliadis, Paul
Isaacs, Richard
Price, David
Moeslein, Fred
Taieb, Julien
Bower, Geoff
Gebski, Val
Van Buskirk, Mark
Cade, David N.
Thurston, Kenneth
Gibbs, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1723 - +
[35] First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
Muro, K.
Watanabe, J.
Shitara, K.
Yamazaki, K.
Ohori, H.
Shiozawa, M.
Yasui, H.
Oki, E.
Sato, T.
Naitoh, T.
Komatsu, Y.
Kato, T.
Hihara, M.
Soeda, J.
Yamamoto, K.
Akagi, K.
Ochiai, A.
Uetake, H.
Yoshino, T.
ANNALS OF ONCOLOGY, 2022, 33 : S377 - S377
[36] Cost-effectiveness analysis of FOLFOXIRI/FOLFOXIRI and mFOLFOX6/FOLFIRI treatment in first-line and second-line chemotherapy for metastatic colorectal cancer
Li, Xianglian
Bao, Jianan
Ma, Jingjing
BMJ OPEN, 2025, 15 (03):
[37] Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
Graham, Christopher N.
Hechmati, Guy
Hjelmgren, Jonas
de Liege, Frederique
Lanier, Julie
Knox, Hediyyih
Barber, Beth
EUROPEAN JOURNAL OF CANCER, 2014, 50 (16) : 2791 - 2801
[38] HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer
Hamilton, Erika P.
Martin, Miguel
O'Sullivan, Ciara Catherine
Curigliano, Giuseppe
Sohn, Joohyuk
Tsurutani, Junji
Tryfonidis, Konstantinos
Santarpia, Libero
Yang, Shan
Dieras, Veronique
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[39] Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
Rivera, Fernando
Valladares, Manuel
Gea, Salvador
Lopez-Martinez, Noemi
JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (06) : 574 - 584
[40] Phase I study of first-line sunitinib (SU) plus modified FOLFOX6 (mFOLFOX6) in Japanese patients (pts) with metastatic colorectal cancer (mCRC)
Hamaguchi, T.
Yoshino, T.
Ohtsu, A.
Yamazaki, K.
Shimada, Y.
Kato, K.
Yasui, H.
Boku, N.
EJC SUPPLEMENTS, 2009, 7 (02): : 340 - 340

← 1 2 3 4 5 →